Table 3.
Top canonical pathways and related differential proteins.
| Ingenuity canonical pathways | −log (P value) | z-score | Proteins |
|---|---|---|---|
| LXR/RXR activation | 7.54 | −1.342 | C4A/C4B, LYZ, ECHS1, APOB, FASN, ACACA, S100A8, MMP9, HADH |
| Fatty acid β-oxidation I | 4.57 | NaN | ECHS1, ECI1, ACSL1, HADH |
| Valine degradation I | 3.87 | NaN | ECHS1, BCKDHA, ALDH6A1 |
| TCA cycle II (eukaryotic) | 3.54 | NaN | CS, SUCLG1, MDH2 |
| Creatine-phosphate biosynthesis | 3.50 | NaN | CKB, CKM |
| Mitochondrial dysfunction | 3.37 | NaN | PDHA1, NDUFA4, CYCS, DHODH, ATP5I, UQCRB |
| Intrinsic prothrombin activation pathway | 3.24 | NaN | COL1A2, FGB, FGG |
| Acetyl-CoA biosynthesis I (pyruvate dehydrogenase complex) | 3.18 | NaN | PDHA1, PDHB |
| Atherosclerosis signaling | 3.16 | NaN | COL1A2, LYZ, APOB, S100A8, MMP9 |
| Ethanol degradation II | 3.07 | NaN | ALDH1B1, ADH1B, ACSL1 |
| Stearate biosynthesis I (animals) | 2.96 | NaN | FASN, ACOT1, ACSL1 |
| Role of IL-17A in psoriasis | 2.62 | NaN | S100A9, S100A8 |
| Acute-phase response signaling | 2.56 | 2 | C4A/C4B, FTL, FN1, FGB, FGG |
z-score was to infer the activation state of pathways. Positive z-score represented that the pathway was activated; negative z-score indicated that the pathway was suppressed.